Adaptive Biotechnologies (ADPT)
(Real Time Quote from BATS)
$4.05 USD
+0.01 (0.25%)
Updated Jul 22, 2024 01:36 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
ADPT 4.05 +0.01(0.25%)
Will ADPT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ADPT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ADPT
Agenus (AGEN) Tanks on Colorectal Cancer Study Interim Data
TEVA's Ajovy Meets Goal in Migraine Prevention Study for Kids
ADPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bayer (BAYRY) Meets Primary Goal in Nubeqa Expanded-Use Study
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans
Arcutis (ARQT) Stock Rises 31% in the Past Month: Here's Why
Other News for ADPT
3 Precision Medicine Stocks Tailoring Treatments
Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024
Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
Adaptive Biotechnologies announces data on MRD assessment with clonoSEQ
Adaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference